Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Public Health

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany

  • Jana Müller1, 2,
  • Daniel Schmidt1, 2Email author,
  • Christian Kollan1,
  • Marc Lehmann3,
  • Viviane Bremer1 and
  • Ruth Zimmermann1
Contributed equally
BMC Public HealthBMC series – open, inclusive and trusted201717:843

https://doi.org/10.1186/s12889-017-4840-4

Received: 16 February 2017

Accepted: 6 October 2017

Published: 25 October 2017

Abstract

Background

In Germany, medical care of prisoners is completely separated from extramural health care. The extent and quality of medical care among prisoners in Germany are therefore largely unknown. We performed a secondary data analysis of pharmacy sales data for tuberculosis (TB), HIV, hepatitis C (HCV) and opioid substitution treatment (OST) delivered to prisons in 11 federal states (FS) in Germany between 01/2012 and 03/2013. The aims of this study were to assess (i) the treatment availability for the selected diseases and OST in German prisons, (ii) the proportion of prisoners treated per FS and overall for TB, HIV, HCV and OST during the study period.

Methods

Substances unique to or typically used for the treatment of each disease were defined as marker substances with defined daily doses (DDD).

For each marker substance we assessed the cumulative number of DDD, the average daily number of DDD (DDDd) and average treatment prevalence per day in percent (adTP). Accordingly, the DDDd represents one person treated per day and the adTP means the proportion of prisoners treated per day. We compared the adTP of the diseases with previously measured prevalences.

Results

We obtained data from pharmacies supplying prisons in 11 of 16 German FS. Of the included prisons, 41% were supplied with medicines for TB, 71% for HIV and 58% for HCV and OST. Twice as many delivered marker substances for TB were indicated for the continuation phase and chemoprevention than the intensive phase. The HIV adTP ranged from 0.06% to 0.94%, HCV adTP ranged from 0.03% to 0.59% and OST adTP ranged from 0% to 7.90%. The overall adTP for the respective treatment was 0.39% for HIV, 0.12% for HCV and 2.18% for OST.

Conclusions

According to our findings treatment rates for TB were consistent with the expected TB prevalence, at least in Berlin. HIV treatment seems to be offered to an adequate proportion of estimated infected prisoners. In contrast, the HCV treatment prevalence was low. High variation among FS in provision of all treatments, particularly of OST, point to inconsistent treatment practices, although nationwide extramural treatment guidelines for Germany exist.

Keywords

TBHIVHCVOSTTreatmentPrison healthIntramuralSecondary data

Background

Studies have shown that specific blood- and air-borne and sexually transmitted infections are more common among prisoners than in the general population: in Germany and other European countries, tuberculosis (TB) prevalence was 11 to 81 times higher, hepatitis C virus (HCV) prevalence was 17 to 100 times higher, human immunodeficiency virus (HIV) prevalence was 5 to 24 times higher and opioid dependence was 70 times higher among prisoners in comparison to the general population [18]. TB is primarily an airborne disease and the bacteria are usually spread from person to person through infectious droplet nuclei when an infectious pulmonary TB patient coughs or sneezes [9]. Usually, a prolonged and close contact is required for transmission; therefore the prison setting can facilitate the spread of the disease. HIV and HCV can be transmitted via unprotected sexual contacts as well as through the widespread intramural practice of unsafe drug use and tattooing involving the sharing of potentially infectious needles, syringes and other paraphernalia [8, 1016]. Thus transmission risks and infection events are highly increased in prisons, especially due to the absence of sterile drug injecting utensils and restricted access to condoms and other prevention measures.

Nevertheless, the prison setting presents not only challenges, but also opportunities for the prevention and treatment of TB, HIV and hepatitis [17]. Prevention of HIV and HCV by offering testing and counselling, providing condoms and tattooing materials as well as sterile injection equipment for people who inject drugs (PWID) also includes the initiation and continuation of opioid substitution treatment (OST) to reduce injection frequency. Furthermore, the treatment of newly diagnosed and already known infections is important not only for the person infected but also in terms of treatment as prevention [6, 1823]. Despite various challenges in providing treatment for the mentioned infectious diseases and offering OST in the prison setting, it is practicable, and crucial to reduce transmission within prisons.

Different screening approaches exist to identify infections in prisons; however, systematic screening for infectious diseases is not implemented in the German prison system. Strategies differ among federal states (FS) and singular prisons. TB screening by chest x-ray is performed systematically on all prisoners at entrance in the FS of Berlin [24], and in some other prisons, but in most FS, symptom-based screening strategies are implemented. Screening for sexually transmitted and blood-borne viruses is also diverse, and ranges from test offer to persons with clinical symptoms or risk factors, request by the prisoner to mandatory testing in some prisons or FS [5].

In Germany, treatment guidelines and effective treatment regimens for TB, HIV and HCV as well as OST are available [2529], and all mentioned treatments are being carried out among patients with statutory health insurance (SHI) extramurally. Upon incarceration SHI is suspended, and health care is provided and paid for by the federal Ministry of Justice (MoJ) of the respective FS. As a result of this transitional period between health care providers treatment interruptions may occur [14, 30].

During the study period from January 2012 to March 2013, 67.607 people were detained in 186 prisons in the 16 FS of Germany [31], corresponding to nearly 0.08% of the total German population. Throughout the study period, five pharmacies supplied all prison hospitals and prisons in Germany with pharmaceuticals. Implementation and provision of health care lays within the responsibility of the MoJ of the respective FS [32]. Nevertheless, according to national laws (Prison Act § 56ff StVollzG; Social Act SGB V), health care in the penitentiary system should take place under the principle of equivalence of care and within the standards of the SHI [14, 33]. Health care is implemented by the prison doctor with the help of the prison administration, both of whom are under the supervision and directives of the FS [14, 34, 35]. Medical care of prisoners is provided by the prison doctor in out-patient care, in special prison wards and correctional hospitals or wherever necessary by extramural specialized medical doctors or hospitals [14]. Since not every prison has a sick ward and only some FS have prison hospitals, contracts and transfer co-operations exist among the states in order to ensure medical care in every FS [34, 3638].

Because prison health care is not part of the regular public health system in Germany, it is therefore not part of the health reporting system [14]. The extent and quality of TB, HIV, HCV and opioid dependence treatment provided to prisoners in Germany are therefore largely unknown [5, 6, 39].

In order to determine the medical care of infectious diseases and opioid dependence among prisoners in Germany we performed a secondary data analysis of pharmacy sales data for TB, HIV, HCV treatments and OST delivered to prisons in 11 FS in Germany between January 2012 and March 2013. The aims of this study were to assess (i) the treatment availability for the selected diseases and OST in German prisons (ii) the proportion of prisoners treated per FS and overall for TB, HIV, HCV and OST during the study period.

Methods

We asked the MoJ of all 16 FS in Germany to approve and support the planned data collection and analysis for each respective FS in August 2013. Twelve FS agreed to participate in the study; however, one FS was excluded because the respective pharmacy did not provide the data. In the participating FS, all prisons and prisoners of the respective FS were included except one sick ward (5 beds) and one correctional hospital (52 beds) because they were not supplied by one of the contract pharmacies. Throughout the study period, all participating prisons and prison hospitals were supplied by three pharmacies with TB, HIV, HCV and OST medicines.

The pharmacies provided the data for the period from 01/2012 to 03/2013. The dataset contained a minimum of eight variables: the name of the prison, the FS, the trade name of the drug, package size, dosage form, the Anatomical Therapeutic Chemical (ATC) classification code of the drug, the central pharmaceutical number (Pharmazentralnummer, PZN), and the number of drug packages supplied per month. The study collected solely prescription data and no individual patient data. No ethical or data protection concerns were raised. The names of the prisons were pseudonymized.

Substances unique to or typically used for the treatment of each disease were defined as marker substances for the respective disease. We used defined daily doses (DDD) of the marker substances to calculate the number of daily treated persons. The DDD were determined based on current national treatment guidelines, prescribing information according to the German Medicines Act and literature research (Table 1). The number of standard units (e.g. tablets, pens) was determined for each marker substance.
Table 1

Marker substances and DDD

Disease

Marker substances

DDD [mg]

Tuberculosis [26, 58]

Ethambutol (E)

1200

Pyrazinamid (Z)

1500

Isoniazid (H)

300 a

Rifampicin (R)

600

Protionamide (Pto)

750

Terizidone (Trd)

750

Rifabutin (Rfb)

150

Hepatitis C [27, 5860]

Pegylated interferon-α (PEG-INF)

0.05, 0.08, 0.1, 0.12, 0.135, 0.15, 0.18

Boceprevir (BOC)

2400

Telaprevir (TVR)

2250

HIV [25, 58]

Emtricitabin (FTC)

200

Lamivudin (3TC)

300

Opioid dependence [29, 6164]

Methadone,

90

Levomethadone

45

Buprenorphine

8

Buprenorphine/Naloxone

8

aFor the formulation of 400 mg isoniazid per pill the determined DDD was 400 mg

First, we assessed the cumulative number of DDD (DDDcum) of the marker substances for the whole study period (456 days). Then we calculated the average daily number of DDD for each marker substance for the study period (DDDd). Accordingly the DDDd represents one person treated with the respective substance per study day. Finally, we calculated the average treatment prevalence per day in percent (average daily treatment prevalence, adTP). Accordingly, the adTP means the proportion of prisoners treated per day with the respective drug to the average number of all prisoners during the study period (Fig. 1). We compared the adTP with previously measured prevalences.
Fig. 1

Cumulative number of DDD, average daily number of DDD and average daily treatment prevalence

The number of incarcerated persons was obtained from the German Federal Statistical Office, which provides this data in March, August and November each year [31]. Based on these data an average monthly number of prisoners for the months of March 2012, August 2012, November 2012 and March 2013 were calculated for each participating FS and for all participating states in total (Fig. 2).
Fig. 2

Average number of prisoners per month in the respective FS and in total during the study period January 2012 and March 2013. Bavaria (BY), Berlin (BE), Bremen (HB), Hamburg (HH), Mecklenburg-Western Pomerania (MV), Lower Saxony (NI), Saarland (SL), Saxony (SN), Saxony-Anhalt (ST), Schleswig-Holstein (SH) and Thuringia (TH)

TB treatment

A standard six month treatment regimen for TB consists of the four antitubercular substances ethambutol (E), pyrazinamid (Z), isoniazid (H) and rifampicin (R). Patients receive all four drugs daily for the first two months (intensive phase), followed by H and R daily for another four months (continuation phase). The marker substances for anti-TB standard treatment were determined to be E, Z, H and R. The determined DDD were 1200 mg for E, 1500 mg for Z, 300 mg for H (except for the formulation 400 mg per pill) and 600 mg for R as recommended in the ATC classification (Table 1). The standard regimen for latent tuberculosis infection (chemoprevention) consists of either (i) H alone or (ii) a combination of H and R or (iii) R alone [26]. For chemoprevention the marker substances were determined to be H (DDD 300 mg) and/or R (DDD 600 mg). R and H fixed-dose combinations were divided into single substances. Pyridoxin as an additive to H was not taken into account. For multidrug-resistant-TB (MDR-TB), protionamide (Pto) and terizidone (Trd) were determined to be the marker substances with a DDD of 750 mg. For HIV-TB-coinfection the marker substance was rifabutin (Rfb) with a DDD of 150 mg (Table 1).

HIV treatment

The standard therapy for HIV during the study period contained exactly one thiacytidine medication (TCM), either lamivudine (3TC) or emtricitabine (FTC). The marker substances for HIV treatment were determined to be 3TC and FTC (Table 1) [25, 40, 41]. The determined DDD were 300 mg for 3TC and 200 mg for FTC. Drugs with more than one substance were split into single substances.

HCV treatment

The standard therapy for HCV during the study period consisted of peginterferon α-2a (PEG-IFN α-2a) or peginterferon α-2b (PEG-IFN α-2b) in combination with ribavirin (RBV). Furthermore, during the study period a triple-therapy with the substances boceprevir (BOC) or telaprevir (TVR) in combination with PEG-IFN and RBV was available. The marker substances for HCV treatment were determined to be PEG-IFN α-2a, PEG-IFN α-2b, BOC and TVR. We assumed that one pen PEG-IFN correlated with one treated person. The determined DDD were 2400 mg for BOC and 2250 mg for TVR (Table 1).

OST

The marker substances for OST were determined to be methadone, levomethadone, buprenorphine and buprenorphine/naloxone. The determined DDD were 90 mg for methadone, 45 mg for levomethadone, and 8 mg for buprenorphine and buprenorphine/naloxone (Table 1).

Results

By June 2014, of the total 16 German FS, the MoJ of the 12 FS Bavaria, Berlin, Bremen, Hamburg, Mecklenburg-Western Pomerania, Lower Saxony, Rhineland Palatinate, Saarland, Saxony, Saxony-Anhalt, Schleswig-Holstein and Thuringia had agreed to the study. Rhineland Palatinate could not deliver the data and was excluded. In the study period the 11 participating FS with 34,191 prisoners in 97 prisons represented almost half of all German prisoners (N = 67,607) in 186 prisons (Fig. 3).
Fig. 3

Participation in the study and number of prisons in the respective FS of Germany

Detailed results for each disease and FS are shown in Table 2.
Table 2

Number of prisons, number of delivered prisons, average number of prisoners, cumulative number of DDD (DDDcum), average daily number of DDD (DDDd) and average treatment prevalence per day in percent (adTP)

Federal state

Bavaria

Berlin

Bremen

Hamburg

Mecklenburg-Western Pomerania

Lower Saxony

Saarland

Saxony

Saxony-Anhalt

Schleswig-Holstein

Thuringia

Overall

Number of prisons

36

8

1

6

5

12

2

10

5

6

6

97

Average number of prisoners (03/2012, 08/2012, 11/2012, 03/2013)

11,914

4193

573

1627

1316

5159

859

3493

1952

1341

1764

34,191

Number of prisons with delivery of TB drugs

13

3

1

4

2

9

0

2

3

3

3

40

 H DDDcum

3636

2484

251

1877

167

1734

0

100

2351

500

333

13,432

 R DDDcum

4640

2455

293

1633

100

1050

0

140

790

85

0

11,185

 E DDDcum

2037

1440

135

1209

0

271

0

242

42

0

104

5480

 Z DDDcum

1653

1965

134

1101

0

300

0

67

100

0

0

5319

 Pto DDDcum

0

100

0

0

0

0

0

0

0

0

0

100

 Trd DDDcum

251

284

0

0

0

0

0

0

0

0

0

534

 RFB DDDcum

405

0

0

0

0

0

0

0

0

0

105

510

 H DDDd

8

5

1

4

0

4

0

0

5

1

1

29

 R DDDd

10

5

1

4

0

2

0

0

2

0

0

25

 E DDDd

4

3

0

3

0

1

0

1

0

0

0

12

 Z DDDd

4

4

0

2

0

1

0

0

0

0

0

12

 Pto DDDd

0

0

0

0

0

0

0

0

0

0

0

0

 Trd DDDd

1

1

0

0

0

0

0

0

0

0

0

1

 RFB DDDd

1

0

0

0

0

0

0

0

0

0

0

1

 H adTP

0.067

0.130

0.096

0.253

0.028

0.074

0.000

0.006

0.264

0.082

0.041

0.086

 R adTP

0.085

0.128

0.112

0.220

0.017

0.045

0.000

0.009

0.089

0.014

0.000

0.072

 E adTP

0.037

0.075

0.052

0.163

0.000

0.012

0.000

0.015

0.005

0.000

0.013

0.035

 Z adTP

0.030

0.103

0.051

0.148

0.000

0.013

0.000

0.004

0.011

0.000

0.000

0.034

 Pto adTP

0.000

0.005

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.001

 Trd adTP

0.005

0.015

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.003

 RFB adTP

0.007

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.013

0.003

Number of prisons with delivery of HIV drugs

20

7

1

6

3

12

2

7

3

5

3

69

 non-TCM DDDcum

42,224

32,784

5060

11,950

3060

24,770

4230

3000

2580

5850

840

136,348

 TCM DDDcum

18,900

14,520

2460

6210

660

11,236

1980

960

1290

2730

510

61,456

 non-TCM DDDd

93

72

11

26

7

54

9

7

6

13

2

299

 TCM DDDd

41

32

5

14

1

25

4

2

3

6

1

135

 Ratio non-TCM/TCM

2.2

2.3

2.1

1.9

4.6

2.2

2.1

3.1

2.0

2.1

1.6

2.2

 HIV adTP

0.348

0.759

0.941

0.837

0.110

0.478

0.505

0.060

0.145

0.446

0.063

0.394

Number of prisons with delivery of HCV drugs

17

6

1

2

1

9

1

8

5

3

3

56

 PEG-IFN α-2a DDDcum

3724

1463

1547

1253

0

2198

959

987

1078

1260

448

14,917

 PEG-IFN α-2b DDDcum

392

140

0

0

182

315

0

1925

0

7

0

2961

 Total PEG-IFN α DDDcum

4116

1603

1547

1253

182

2513

959

2912

1078

1267

448

17,878

 BOC DDDcum

70

84

56

0

0

0

0

245

0

0

0

455

 TVR DDDcum

147

49

0

0

0

455

0

0

84

84

49

868

 PEG IFN α-2a DDDd

8

3

3

3

0

5

2

2

2

3

1

33

 PEG IFN α-2b DDDd

1

0

0

0

0

1

0

4

0

0

0

6

 Total PEG-IFN α DDDd

9

4

3

3

0

6

2

6

2

3

1

39

 BOC DDDd

0

0

0

0

0

0

0

1

0

0

0

1

 TVR DDDd

0

0

0

0

0

1

0

0

0

0

0

2

 PEG-IFN α adTP

0.076

0.084

0.592

0.169

0.030

0.107

0.245

0.183

0.121

0.207

0.056

0.115

 BOC adTP

0.001

0.004

0.021

0.000

0.000

0.000

0.000

0.015

0.000

0.000

0.000

0.003

 TVR adTP

0.003

0.003

0.000

0.000

0.000

0.019

0.000

0.000

0.009

0.014

0.006

0.006

Number of prisons with delivery of OST

7

6

1

5

3

13

0

6

5

5

5

56

 Buprenorphine DDDcum

119

10,738

0

154

2142

910

0

434

3073

1225

1460

20,255

 Buprenorphine/Naloxone DDDcum

756

3598

0

0

0

3248

0

175

77

 

119

7973

 Levomethadone DDDcum

222

18,556

222

0

1172

48,937

0

1444

6182

16,512

3043

96,292

 Methadone DDDcum

2033

27,967

20,411

47,472

 

98,590

0

  

19,579

 

216,052

 Total OST DDDcum

3131

60,859

20,633

47,626

3314

151,684

0

2053

9332

37,316

4622

340,571

 Buprenorphine DDDd

0

24

0

0

5

2

0

1

7

3

3

44

 Buprenorphine/Naloxone DDDd

2

8

0

0

0

7

0

0

0

0

0

17

 Levomethadone DDDd

0

41

0

0

3

107

0

3

14

36

7

211

 Methadone DDDd

4

61

45

104

0

216

0

0

0

43

0

474

 Total OST DDDd

7

133

45

104

7

333

0

5

20

82

10

747

 Buprenorphine adTP

0.002

0.562

0.000

0.021

0.357

0.039

0.000

0.027

0.345

0.200

0.182

0.130

 Buprenorphine/Naloxone adTP

0.014

0.188

0.000

0.000

0.000

0.138

0.000

0.011

0.009

0.000

0.015

0.051

 Levomethadone adTP

0.004

0.970

0.085

0.000

0.195

2.080

0.000

0.091

0.695

2.700

0.378

0.618

 Methadone adTP

0.037

1.463

7.812

6.399

0.000

4.191

0.000

0.000

0.000

3.202

0.000

1.386

 OST adTP

0.058

3.183

7.897

6.419

0.552

6.448

0.000

0.129

1.048

6.102

0.575

2.184

TB treatment

About 41% of the 97 prisons were supplied with medicines against TB. There was no TB medicine supply at all to prisons in Saarland. Both marker substances E and Z for the intensive phase were delivered to all investigated FS except for Mecklenburg-Western Pomerania, Schleswig-Holstein and Thuringia. Both marker substances H and R for the continuation phase and chemoprevention were supplied to all FS except Thuringia. Mecklenburg-Western Pomerania and Schleswig-Holstein only received the marker substances H and R, Thuringia only the substances E and H. Substances for the treatment of drug resistant or complicated or severe TB were provided in the FS Bavaria, Berlin and Thuringia.

The adTP of E and Z in the initial stage ranged from 0% in Mecklenburg-Western Pomerania, Saarland, Schleswig-Holstein and Thuringia (Z) to 0.16% (E) and 0.15% (Z) in Hamburg. The adTP of H and R in the continuity stage ranged from 0% in Saarland and Thuringia (R) to 0.26% in Saxony-Anhalt (H) and 0.22% in Hamburg (R). In total, twice as many delivered marker substances were indicated for the continuation phase and chemoprevention than the intensive phase (H & R: 0.09% & 0.07% vs. E & Z: 0.04% & 0.03%). The formulation 400 mg isoniazid per pill played only a marginal role in Lower-Saxony, Saxony-Anhalt and Schleswig-Holstein. Pto as a marker substance for MDR-TB treatment was only delivered in Berlin (adTP 0.01%). Trd also as a marker substance for MDR-TB was delivered in Bavaria (adTP 0.01%) and Berlin (adTP 0.02%). Rfb as marker substance for the TB treatment of patients with HIV-TB-coinfection was delivered in Bavaria (adTP 0.01%) and Thuringia (adTP 0.02%).

HIV treatment

Overall, 71% of the included prisons in the respective FS were delivered with drugs for HIV treatment. HIV DDDcum ranged from 510 in Thuringia to 18.900 in Bavaria. HIV DDDd ranged from 1 in Thuringia to 41 in Bavaria. HIV adTP ranged from 0.06% in Saxony to 0.94% in Bremen. The overall HIV adTP was 0.39%.

Nucleoside reverse transcriptase inhibitor (NRTI) substances and protease inhibitor (PI) substances were supplied to all participating FS. With the exception of Thuringia, all other FS were supplied with non-nucleoside reverse transcriptase inhibitor (NNRTI) substances and the integrase inhibitor (INI) raltegravir. The entry inhibitor (EI) maraviroc was supplied exclusively to Bavaria and Berlin.

HCV treatment

In total, 58% of the represented prisons were delivered with drugs for HCV treatment. In the FS of Bremen and Saxony-Anhalt, all prisons were supplied with HCV drugs. HCV DDDcum ranged from 182 in Mecklenburg-Western Pomerania to 4.116 in Bavaria. HCV DDDd ranged from 0 in Mecklenburg-Western Pomerania to 9 in Bavaria. HCV adTP ranged from 0.03% in Mecklenburg-Western Pomerania to 0.59% in Bremen. The overall HCV adTP was 0.12%. BOC DDDcum ranged from 0 in seven FS to 245 in Saxony. BOC DDDd ranged from 0 in seven FS to 1 in Saxony. BOC adTP ranged from 0% in seven FS to 0.02% in Bremen. TVR DDDcum ranged from 0 in five FS to 455 in Lower-Saxony. TVR DDDd ranged from 0 in five FS to 1 in Lower-Saxony. TVR adTP ranged from 0% in five FS to 0.02% in Lower-Saxony.

OST

Regarding opioid substitutions, 58% of the included prisons in the respective FS were supplied with drugs for OST. OST DDDcum ranged from 0 in Saarland to 151.684 in Lower-Saxony. OST DDDd ranged from 0 in Saarland to 333 in Lower-Saxony. OST adTP ranged between 0% in Saarland and 7.90% in Bremen. The overall OST adTP was 2.18%.

Discussion

The results show that medical treatment of all investigated diseases took place in German penal institutions. However, under the assumption that the number of adTP corresponds to the number of treated people per day, differences in quantity and extent of treatment were observed among the FS. To what extent requirements and directives of the MoJ affect the initiation of treatment and health care seems to differ not only among FS but also among prisons within the FS [35, 42, 43]. The differences regarding treatment of diseases and OST in prisons might reflect the decentralized federal system in Germany, in which the states may pursue different approaches with respect to the management of medical care [5, 6, 39].

TB treatment

Our data suggests intensive and continued tuberculosis treatments as well as chemoprevention in prisons of all participating FS except Saarland, where no TB medicine supply was observed. The treatment of resistant, complicated or severe TB was carried out in the FS Bavaria, Berlin and Thuringia. The federal city-states Berlin, Bremen and Hamburg showed high treatment prevalences for all TB substances, which implies largely initiated and continued TB treatment in those penal institutions. In Mecklenburg-Western Pomerania, Saarland and Schleswig-Holstein TB treatment was not initiated since these FS were not supplied with E and Z. However, Mecklenburg-Western Pomerania, Lower-Saxony, Saxony-Anhalt and Schleswig-Holstein showed high adTP of H and R which suggest mostly continued TB treatment and chemoprevention. In addition, Thuringia showed solely high H adTP, which might also indicate chemoprevention. A further indication of H is the treatment of R-resistant TB. However, since the proportion of corresponding E and Z is too low in the respective FS this may play only a marginal role [26]. Further, we observed a ratio of the marker substances for the intensive and continuation phase that might indicate incomplete standard six-month regimen in most FS. However, since imprisonment can begin or end during the course of a treatment, our observation period did not necessarily capture the entire treatment time.

In all penal institutions in Berlin, each newly incarcerated person is screened for TB by chest x-ray [24]. This active case-finding when entering prison can be equated with the prevalence of TB at the time of imprisonment [24]. Bös and Hauer found a TB prevalence of 0.11% through active case-finding by chest x-ray examinations in 2007–2010 in Berlin’s penal institutions and 0.21% in 1996–1998 [24, 44]. Our work found an adTP in Berlin of 0.08% and 0.10% for the marker substances E and Z, respectively. Comparing the most recent TB prevalence seen in Berlin’s penal institutions to the adTP from our analysis, treatment rates for TB were at least in Berlin consistent with the expected TB prevalence. The most important reason for not treating a prisoner in the study by Bös et al. was a too short duration of imprisonment [24]. We found an almost equal distribution of the adTP for H and R possibly explained by the active case-finding in Berlin with no need for chemoprevention.

Treatment of Multidrug-Resistant-TB and of complicated or severe TB were each observed in only two FS, Berlin and Bavaria and Thuringia and Bavaria, respectively. This was possibly due to a transfer of patients to prison hospitals with necessary existing technical and logistical conditions.

The large range of the provision of drugs for TB treatment among the FS could be explained by co-operations between FS. Especially the co-operation of Saarland with Bavaria and North Rhine-Westphalia might be the reason why there was no TB treatments at all supplied to prisons in Saarland. According to this arrangement Saarland transferred TB infected male prisoners to Bavaria and TB infected female prisoners to North Rhine-Westphalia for treatment. Also Thuringia had a co-operation with Bavaria and transferred TB infected prisoners to Bavaria. However, TB treatments were still carried out in Thuringia with H, E and Rfb, and the latter is indicated for HIV-TB-coinfected patients. We speculate the reason why TB treatments were still carried out in Thuringia despite existing co-operations could be overcrowding or other factors that would need further investigation.

HIV treatment

HIV treatments were carried out in prisons of all participating FS, with highest treatment prevalences found in the federal city-states Bremen, Hamburg and Berlin. The higher HIV adTP compared to the HCV adTP is remarkable, especially considering that studies found a much lower HIV prevalence compared to the HCV prevalence among prisoners. Radun et al. found an HIV antibody prevalence of 0.7% [3]. Schulte et al. came to an HIV prevalence of 1.2%. In this study, 147 prisoners were treated against HIV per year corresponding to 1.0% of all represented prisoners and to 89% of the infected prisoners [5]. In a study by Reimer et al., 300 prisoners were treated corresponding to about 1.0% of the represented prisoners and to about 94% of the infected prisoners [39]. Our results are in accordance with these previous studies, and the treatment prevalence of 0.39% for HIV matches more or less the expected prevalence of infection. HIV treatment seems to be the only of the four investigated treatments that is offered to an adequate proportion of estimated infected prisoners.

The combination of the agents and drug classes suggest treatment according to treatment guidelines which recommend a combination of two NRTI with either a NNRTI, PI or INI for first line therapy. The proportion of NRTI DDDcum to total NNRTI, PI and INI DDDcum suggests standard regimen distribution. Additionally, within the drug classes the DDDcum of the drugs correspond to a standard regimen. Substances differing from the standard therapy were rarely administered. This applies, for example, to the older NRTI substance didanosin and the nowadays less frequent PI substance fosamprenavir. On the other hand, newer substances were also prescribed rather infrequently, which could indicate a hesitation to apply them. This is clearly seen in rilpivirin in the substance group of the NNRTI. Furthermore, we found indication for continuation and switch of ART of previously treated prisoners. This can be seen through the delivery of etravirin in Bavaria, Hamburg and Saarland, which is indicated for the treatment in antiretroviral treatment-experienced patients.

HCV treatment

Our data suggest that HCV treatments were provided in prisons of all participating FS. Overall, during the observation period, only 0.12% of prisoners were treated per day with HCV antivirals. This HCV treatment prevalence appears to be too low considering that studies have shown HCV prevalences to be about 14% to 21% among prisoners [3, 5, 39]. In the comparison of the FS, Bremen showed the highest HCV treatment prevalence, followed by Saarland and Schleswig-Holstein. In the two other federal city-states Berlin and Hamburg very low HCV treatment prevalences were observed, which is not consistent with the high HIV treatment prevalence in both cities. The one third lower adTP in Berlin compared to the overall adTP was therefore surprising considering Berlin has the highest incidence of newly diagnosed HCV of all FS [45], and risk group populations are disproportionately present. We assume that the prevalence of HCV and the need of treatment among prisoners differ from prison to prison depending on the proportion of prisoners from FS with higher HCV prevalence, the proportion of PWID among prisoners, as well as the proportion of prisoners originating from countries with high HCV prevalence. Also, intra- and extramural co-operations among FS may at least partially explain the different treatment prevalences [46]. Although studies found a much higher HCV prevalence than HIV prevalence among prisoners [3, 5, 39] the amount of HCV treatment per prisoner is much lower than of HIV treatment.

Furthermore, the observed HCV treatment prevalence in view of the high HCV antibody prevalence of 20.6%, 14.3% and 15.0% found among prisoners in surveys is much too low [3, 5, 39]. These studies in German prisons found low HCV treatment rates and support our findings, only 111 (0.8% of the represented prisoners) and 400 (1.4% of the represented prisoners) prisoners were treated per year [5, 39]. According to Schulte et al., the main exclusion criteria for HCV treatment were short duration of imprisonment and drug abuse [5]. Also in comparison to the prevalence of injecting drug use (IDU) by Radun et al. (29.7%) and Schulte et al. (21.9%), the HCV adTP of 0.12% appeared to be too low considering that studies have shown HCV antibody prevalences of 57.6% among PWID [3, 5, 27]. Furthermore according to current guidelines, IDU is no contraindication for HCV therapy [27].

At the time of the analysis, HCV was treated in particular with a dual combination of PEG-IFN and RBV according to the respective guidelines at that time. There was also the option of a triple therapy with one of the two protease inhibitors BOC or TVR in combination with PEG-IFN and RBV. However, this treatment was cost extensive and rich in side effects and assumedly therefore played virtually no role for the HCV treatment in prisons. Triple therapies containing BOC or TVR accounted for only 7.8% of all HCV treatments. Sligthly more triple therapies were observed in Berlin and about two times more in Bremen, Lower Saxony and Saxony. In 2013, new promising direct-acting antivirals (DAAs) against HCV had already been announced. It is possible that the low treatment numbers are partially related to the awaiting of upcoming treatment options as an analysis of drug prescription data of the general German population also suggests [47]. Furthermore, due to the relative ineffectiveness and often serious side effects of interferon-based treatment, it seems plausible that prisoners are even less likely to wish to undergo debilitating treatment than non-prisoners. However, it is unknown to what extent costly DAA regimens have been prescribed since 2014 in the prison setting. An investigation of that would be a valuable follow-up assessment of the extent and quality of medical treatment in German prisons.

OST

We found a large range of the OST adTP between 0% in Saarland and 7.9% in Bremen. Thus, in some FS OST seems to be provided to a high proportion of prisoners, indicating a more liberal and harm-reduction-led politic. In the northern FS more prisoners had access to OST compared to Saarland and Bavaria and the eastern FS [46]. None of the prisons in Saarland and only seven penal institutions in Bavaria were supplied with OST medicines. The amount of OST doses suggests therapy in the northern FS and an abstinence and denial approach in Saarland, Bavaria and the eastern FS. This imbalance and therapy slope among the FS was already described by Keppler et al. [33, 46].

The low number of OST-supplied penal institutions in Bavaria is remarkable. Although OST needs no special medical tools or rooms and is simple to carry out only 7 of the 36 prisons were supplied with OST substances in Bavaria, corresponding to an OST adTP of 0.06%. Due to this low OST adTP, we assume a practice of denial or withdrawal rather than substitution treatments offered to prisoners in Bavaria [48]. The number of 133 DDDd OST we found in Berlin correlates well with the number of 154 and 120 OST reported for Berlin prisons by Keppler in Lehmann et al. [46] and by Jakob et al. [35]. According to this, 3.6% of the prisoners in Berlin received OST compared to 3.2% in our study [46]. Schulte et al. accounted for 1,137 OST per year altogether, which corresponds to 8.0% of the represented prisoners and to 37% of the PWID in prison [5]. In Reimer’s work, 320 long time opioid substitutions correspond to about 1.1% of the represented prisoners [39]. The overall OST adTP of 2.18% we found in our study approximately matches the OST treatment prevalence of Schulte et al. and Reimer. However, given the IDU prevalence of 29.7% and 21.9% among prisoners found in other studies [3, 5], even in the FS with a comparably high OST prevalence it can be concluded that only a minority of prisoners in need receive OST. Reporting on the prevalence of opioid dependence among people in prison was recently implemented in Germany, but the data is not yet published. It might be assumed that IDU mostly consists of opioid consumption. It is possible that some people coming into prison want to use the opportunity to be treated and to stop injecting but that others might prefer a cold withdrawal or do not want to reveal their addiction to avoid stigmatization or disadvantages concerning their prison conditions. Nonetheless our data show a need for scaling up OST, at least in some of the FS.

About 25% of the male and 50% of the female prisoners in Germany are PWID [33]. OST provided during incarceration reduces the level of IDU in prison and thus the possibility of HIV and HCV transmission via unsafe use [49]. OST as an approved effective therapy functions well in a prison setting, e.g. supervised application, regularity of intake and structured daily life [33]. OST, particularly in combination with other harm-reduction strategies, is an evidence-based measure of HIV and HCV prevention [16, 50, 51]. In addition, people who receive OST often show an increased compliance regarding antiviral and antiretroviral treatment [52, 53]. For the above mentioned reasons and its protective effects, it is incomprehensible that OST is not offered in every prison. According to information provided by several prison doctors a certain proportion of PWID and thus, people in potential need of OST, are among every prison population, and no distribution of PWID to special prisons takes place. Further, this would not explain the high range of OST among the FS, suggesting an abstinence-oriented and denial approach in some FS.

IDU in prison is often unsafe due to the unavailability of sterile materials and is therefore one of the main transmission routes and major risks for HCV. Studies have shown an HCV antibody prevalence of 57.6% among PWID [3] therefore, the HCV adTP of 0.12% appeared to be too low compared to the OST adTP of 2.18%. Studies revealed that OST access depended mainly on substitution treatment before imprisonment, short duration of imprisonment and co-morbidity such as infectious diseases [5, 42].

Although OST guidelines exist for Germany [54], this work shows that these guidelines are not consistently applied, and that intramural OST highly differs among the FS and prisons. This might be due to the lack of nationwide OST guidelines for prisons [35]. However, in the absence of prison-specific guidelines the existing national OST guidelines should be applied to prisoners as well.

Limitations

The following limitations have to be considered in the interpretation of the data.

The evaluation of pharmacy delivery data allows no statement about which and how many medicines actually reached the individual patient. This can potentially lead to an overestimation of the calculated DDD for all evaluated drugs because they can be ordered in advance. On the other hand, emergency or ad hoc-orders are taken over by local pharmacies not included in our analysis, leading to a potential underestimation of the data and the corresponding treatments. However, according to a prison-supplying pharmacy, emergency orders amount to less than 2% [55]. Furthermore, one drug package might be used for several patients. Usually, the pills are packaged according to the prescription per patient or per patient and day [56]. We tried to avoid a bias by calculating the treatment prevalence per day. Tablets are divided only in particular cases. However, this procedure can differ from prison to prison. In addition, there are differences in the treatment management and the supply of medication in case of transfers of prisoners. In some cases, medicines are completely provided by the previously responsible prison. In other cases, after the transfer to another prison, the medicines are provided by the new prison [56].

The treatment success and failure, including side effects and drug interactions, remain unknown. We had no knowledge of the treatment duration. Therefore we calculated the average treatment prevalence as point prevalence in percent at each single day of the whole study period. For OST we did not consider initial dosage or gradual reduction of OST, but assumed a steady dosage, so we might have underestimated the number of persons under OST medication.

Because of the missing pharmacy data of one sick ward in a prison in Mecklenburg-Western Pomerania with five beds and one correctional hospital in Lower Saxony with 52 beds, the data of Mecklenburg-Western Pomerania and Lower Saxony are not complete. Therefore the DDD and adTP in these FS might be underestimated.

Several co-operations exist among the FS limiting the representativeness of the data for the respective FS. For example, Saarland had a contract to transfer ill prisoners to Rhineland-Palatinate [36]. Schleswig-Holstein had a transfer co-operation with Hamburg [37]. Thuringia had co-operations with Saxony, Saxony-Anhalt and Hessen to transfer ill prisoners [38]. Therefore the DDD and adTP of Saarland, Schleswig-Holstein and Thuringia are potentially underestimated and of Hamburg, Saxony and Saxony-Anhalt are potentially overestimated.

A further limitation is the different temporal units of the pharmacy delivery data on the one hand (per quarter of a year) and the number of the prisoners on the other hand (four calendar months). The actual duration of imprisonment as well as the information on releases such as the day of the release and the number of released prisoners cannot be derived from the available data and remain unknown. Therefore we chose to account the DDD for each day in the study period.

Moreover, this paper describes merely the proportion of treated persons among all prisoners and not among infected prisoners. To evaluate our treatment prevalence, we compared it with the prevalence seen in previous studies.

Conclusions

This work is the first attempt to describe and assess the medical care of TB, blood-borne and sexually transmitted infections and OST in prison. The study indicates that treatment of TB, HCV, HIV and opioid dependence is carried out in German penal institutions, and that guideline-recommended substances and standard treatments are used. However, a high variation of treatment per prison population was observed among the FS and among the respective diseases, which is not fully explained by the described transfer co-operations. Providing treatment of chronic infections and OST to prisoners seems to be dependent on structural and individual factors, e.g. the prison’s medical service structure, the political attitude and the allocation of financial budget to medical treatment in the respective prison and in the FS. The WHO recommendations and the UN’s Mandela Rules maintain that prisoner health care should be consistent with the community standards of care, and under the direction of the ministry of health [57]. According to our findings, prison health care and policy in Germany is not fully consistent with this, especially with regard to treatment of HCV and OST. Treatment rates for TB were consistent with the expected TB prevalence, at least in Berlin. Treatment for HIV seems to be the one that is offered to a more or less adequate proportion of estimated infected prisoners in the FS. In the view of the expected high HCV prevalence among prison populations and in comparison to HIV and opioid dependence treatment prevalence, the HCV treatment prevalence we observed was too low. HCV treatment with DAAs has improved remarkably since the study period and will hopefully have an impact on the treatment prevalence in prisons despite high costs. Despite a varying proportion of PWID among prisoners and limitations due to a purely secondary data analysis, the large differences among the FS regarding all infection treatments and OST point to inconsistent treatment practices although nationwide extramural treatment guidelines for Germany exist. It is alarming that some FS seem to provide OST at a very low level. However, in some FS our data suggest that a high proportion of prisoners is covered with OST.

Despite its challenges, the prison setting is an opportunity for prevention and treatment of TB, HIV, HCV and OST [18] which could be carried out at a greater extent and more consistently. The regulated environment offers good requirements for e.g. distribution of sterile injection utensils, supervised application, regularity of intake and the opportunity for restructuring of daily life. Prisons therefore provide both risks for the spread of diseases but also many opportunities for prevention of these infections [17]. Continuous analyses for longer periods are necessary in order to make further statements regarding the health care situation in German prisons. A monitoring and reporting system of infectious diseases among prisoners would help to ensure equal access to treatment and to harmonize strategies among FS. Finally, correctional facilities should consistently implement prevention and harm-reduction measures such as needle-exchange and condom distribution programs to avoid further spread of diseases [30].

Notes

Abbreviations

3TC: 

Lamivudine

adTP: 

Average daily treatment prevalence

ART: 

Antiretroviral therapy

ATC: 

Anatomical Therapeutic Chemical

BOC: 

Boceprevir

DAA: 

Direct-acting antiviral

DDD: 

Defined daily dose(s)

DDDcum

Cumulative number of DDD

DDDd

Average daily number of DDD

E: 

Ethambutol

EI: 

Entry inhibitor

FS: 

Federal state(s)

FTC: 

Emtricitabine

H: 

Isoniazid

HCV: 

Hepatitis C virus

HIV: 

Human immunodeficiency virus

IDU: 

Intravenous drug use

INI: 

Integrase inhibitor

MDR-TB: 

Multidrug-resistant-TB

MoJ: 

Ministry of Justice

NNRTI: 

Non-nucleoside reverse transcriptase inhibitor

NRTI: 

Nucleoside reverse transcriptase inhibitor

OST: 

Opioid substitution treatment

PEG-IFN α-2a: 

Peginterferon α-2a

PEG-IFN α-2b: 

Peginterferon α-2b

PEG-IFN: 

Peginterferon

PI: 

Protease inhibitor

Pto: 

Protionamide

PWID: 

People who inject drugs

PZN: 

Central pharmaceutical number

R: 

Rifampicin

RBV: 

Ribavirin

Rfb: 

Rifabutin

SGB: 

Social Act

SHI: 

Statutory health insurance

StVollzG: 

Prison Act

TB: 

Tuberculosis

TCM: 

Thiacytidine medication

Trd: 

Terizidone

TVR: 

Telaprevir

Z: 

Pyrazinamid

Declarations

Acknowledgements

The authors thank the involved Ministries of Justice for their consent to the use of the data, and the pharmacies Hubertus Apotheke in Berlin, Stern-Apotheke in Magdeburg, Saxony-Anhalt, and Wald-Apotheke in Wahlstedt, Schleswig-Holstein for providing the data. We especially thank Tina Warning, Dr. Frank Intert and Roland Rutschke for the good cooperation. The authors would like to thank Barbara Hauer and Lena Fiebig for their helpful comments on the TB results. We further thank Ulrich Peiffer, who as a prison doctor helped us to understand medical issues from a prison viewpoint, as well as Sabine Mauruschat and Michael Janßen for giving advice in treatment-related issues. Thank you to Stefanie Castell, who also supported the interpretation of the data. We are grateful to Prof. Dr. Heino Stöver for his steady interest in this work. We thank Katie Ann Jacques for her critical feedback and advice on this article.

Funding

No specific funding was received for this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

The original datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JM contributed to the conception of the study and study design, managed the data collection, performed the data analysis, interpreted the data, and drafted the manuscript. DS supported JM in data analysis, interpretation and drafted the manuscript. CK devised the estimation approach, performed the data analysis and interpretation of the data and was responsible for database management. ML contributed to the conception of the study, supported the interpretation of the results, and revised the manuscript. VB was responsible for the study design and revised the manuscript. RZ was responsible for the conception of the study and the study design, managed the data use, and contributed to the interpretation of the results and the writing of the manuscript. All authors participated in the critical discussion of the results, and all read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

ML was involved in the procurement of medicines from pharmacies in the context of his duties. The other authors, JM, DS, CK, VB and RZ declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Infectious Disease Epidemiology, HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute
(2)
Charité - Universitätsmedizin Berlin
(3)
Head of Medical Services in the Berlin state prison system

References

  1. Marques NM, et al. Seroepidemiological survey of transmissible infectious diseases in a portuguese prison establishment. Braz J Infect Dis. 2011;15(3):272–5.PubMedGoogle Scholar
  2. Meyer MF, et al. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiol Infect. 2007;135(2):274–80.View ArticlePubMedGoogle Scholar
  3. Radun, D., C. Weilandt, and O. Hamouda, Querschnittsstudie zur Prävalenz von Hepatitis B, Hepatitis C, HIV und infektionsrelevantem Risikoverhalten unter Insassen ausgewählter Justizvollzugsanstalten in Deutschland in Verbindung mit einer Befragung von Justizbediensteten zu Wissen, Einstellungen, Risikobewußtsein und Verhalten zu Hepatitis B, Hepatitis C, HIV und Drogenkonsum. Abschlussbericht an das BMG 2007, Robert Koch-Institut, Wissenschaftliches Institut der Ärzte in Deutschland (WIAD e.V.).Google Scholar
  4. Mayer KH, et al. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305–12.View ArticleGoogle Scholar
  5. Schulte B, et al. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates. Int J Prison Health. 2009;5(1):39–44.View ArticlePubMedGoogle Scholar
  6. Stöver H. Drogenabhängige in Haft - Epidemiologie, Prävention und Behandlung in Totalen Institutionen. Suchttherapie. 2012;13(02):74–80.View ArticleGoogle Scholar
  7. Aerts A, et al. Tuberculosis and tuberculosis control in European prisons. Int J Tuberc Lung Dis. 2006;10(11):1215–23.PubMedGoogle Scholar
  8. Christensen PB, et al. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16(11):1043–9.View ArticlePubMedGoogle Scholar
  9. National Institute of Allergy and Infectious Diseases (NIAID). Tuberculosis (TB). 2016 [cited 2016 27 September 2016]; Available from: https://www.niaid.nih.gov/diseases-conditions/tuberculosis-tb.
  10. Teutsch S, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health. 2010;10:633.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Stark K, et al. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997;26(6):1359–66.View ArticlePubMedGoogle Scholar
  12. Jafari S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14(11):13.View ArticleGoogle Scholar
  13. Abiona T, et al. Body art practices among inmates: implications for transmission of bloodborne infections. Am J Infect Control. 2010;38(2):121–9.View ArticlePubMedGoogle Scholar
  14. Keppler K, et al. Prison health is public health! Problems in adapting and implementing health services for prisoners in Germany. Rev Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;53(2):233–44.View ArticleGoogle Scholar
  15. Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91.View ArticlePubMedGoogle Scholar
  16. Arain A, Robaeys G, Stover H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis. 2014;14(Suppl 6):S17.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Dolan K, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.View ArticlePubMedGoogle Scholar
  18. Ginn S. Promoting health in prison. BMJ. 2013;346:f2216.View ArticlePubMedGoogle Scholar
  19. Fazel S, Baillargeon J. The health of prisoners. Lancet. 2011;377(9769):956–65.View ArticlePubMedGoogle Scholar
  20. Jürgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9(1):57–66.View ArticlePubMedGoogle Scholar
  21. Kerr T, Juergens R. Syringe Exchange Programs in Prisons: Reviewing the Evidence. Canadian HIV/AIDS Legal Network. 2004;1:1–7.Google Scholar
  22. Knorr, B., Gesundheit und Prävention in Haft. Klee, J.; Stöver, H.: Drogen, HIV/AIDS, Hepatitis. Ein Handbuch. Berlin, 2004.Google Scholar
  23. Hedrich D, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17.View ArticlePubMedGoogle Scholar
  24. Bös, L., Die Tuberkulosesitation im Berliner Justizvollzug 2007–2010. Master thesis. Berlin: Charité - Universitätsmedizin Berlin, Berlin School of Public Health; 2011.Google Scholar
  25. Deutsche AIDS-Gesellschaft (DAIG), Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. 2012: 41.Google Scholar
  26. Schaberg T, et al. Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German central committee against tuberculosis (DZK), German respiratory society (DGP). Pneumologie. 2012;66(3):133–71.View ArticlePubMedGoogle Scholar
  27. Sarrazin C, et al. Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-infektion. Z Gastroenterol. 2010;48:289–351.View ArticlePubMedGoogle Scholar
  28. Sarrazin C, et al. Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir. Z Gastroenterol. 2012;50(1):57–72.View ArticlePubMedGoogle Scholar
  29. Backmund, M., et al., Leitlinien der Deutschen Gesellschaft für Suchtmedizin (DGS e.V.): Therapie der Opiatabhängigkeit – Teil 1: Substitutionsbehandlung. 2013.Google Scholar
  30. Shrage L. African Americans, HIV, and mass incarceration. Lancet. 2016;388(10049):e2–3.View ArticlePubMedGoogle Scholar
  31. Statistisches Bundesamt. Rechtspflege, Bestand der Gefangenen und Verwahrten in den deutschen Justizvollzugsanstalten nach ihrer Unterbringung auf Haftplätzen des geschlossenen und offenen Vollzugs jeweils zu den Stichtagen 31. März, 31. August und 30. November eines Jahres. 2013.Google Scholar
  32. Bundeszentrale für politische Bildung (bpb). Föderalismusreform. 2015; Available from: http://www.bpb.de/nachschlagen/lexika/recht-a-z/22184/foederalismusreform.
  33. Keppler K, Stöver H, editors. Gefängnismedizin. Medizinische Versorgung unter Haftbedingungen. Stuttgart: Georg Thieme Verlag KG; 2009.Google Scholar
  34. Deutsche AIDS-Hilfe e.V., Betreuung im_Strafvollzug. Ein Handbuch. 5. Auflage 2014, ed. 2014, Berlin.Google Scholar
  35. Jakob L, Stöver H, Pfeiffer-Gerschel T. Suchtbezogene Gesundheitsversorgung von Inhaftierten in Deutschland - eine Bestandsaufnahme. Sucht. 2013;59(1):39–50.View ArticleGoogle Scholar
  36. Ministerium der Justiz, Vollstreckungsplan für das Saarland. Germany: Ministry of Justice Saarland; 2011.Google Scholar
  37. Ministerium für Justiz. Kultur und Europa, Vollstreckungsplan für das Land Schleswig-Holstein. 1998.Google Scholar
  38. Thüringer Justizministerium, Thüringer Verordnung über den Vollstreckungsplan. Germany: Ministry of Justice Thuringia; 2010.Google Scholar
  39. Pfeiffer-Gerschel, T., et al., Bericht 2011 des nationalen REITOX-Knotenpunkts an die EBDD. Deutschland. Neue Entwicklungen, Trends und Hintergrundinformationen zu Schwerpunktthemen. Drogensituation, 2011. 2010.Google Scholar
  40. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013;16(1):18757. Published online 2013 Jun 30. doi:10.7448/IAS.16.1.18757. PMCID: PMC3699697.
  41. Schmidt D, et al. From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. BMC Public Health. 2015;15:252.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Stöver, H., Substitutionsbehandlungen für Opioidabhängige im Justiz-und Maßregelvollzug. Neue Wege in der Suchtbehandlung im Maßregelvollzug, 2011.Google Scholar
  43. Michels I, Stover H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 2007;4:5.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Hauer, B., Die Tuberkulosesituation im Berliner Justizvollzug 1996–1998. Magisterarbeit. Berlin: Technische Universität Berlin, Institut für Gesundheitswissenschaften, Postgradualer Studiengang Public Health; 2001.Google Scholar
  45. Robert Koch-Institut (RKI). Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis C im Jahr 2013. Epidemiologisches Bulletin. 2014;31(2014):275–88.Google Scholar
  46. Lehmann, M., et al., Gesundheit in Haft. Handbuch für Justiz, Medizin, Psychologie und Sozialarbeit. Lengerich: Pabst Science Publishers; 2014.Google Scholar
  47. Zimmermann R, et al. Real-world treatment for chronic hepatitis C infection in Germany: analyses from drug prescription data, 2010–2015. J Hepatol. 2017;67(1):15–22.View ArticlePubMedGoogle Scholar
  48. Schäffler F, Zimmermann S. Drogenabhängigkeit in bayerischen Haftanstalten – Darstellung und Diskussion ausgewählter Ergebnisse einer bayernweiten Umfrage bei ehemals inhaftierten, drogenkonsumierenden Menschen (n = 195). Akzeptanzorientierte Drogenarbeit Acceptance-Oriented Drug Work. 2012;9:25–38.Google Scholar
  49. Dolan K, et al. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy. 2015;26(Suppl 1):S12–5.View ArticlePubMedGoogle Scholar
  50. Spaulding AC, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144(10):762–9.View ArticlePubMedGoogle Scholar
  51. Zampino R, et al. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323–30.View ArticlePubMedPubMed CentralGoogle Scholar
  52. WHO, UNAIDS, UNODC. Effectiveness of interventions to address HIV in prisons. Evidence for action technical papers. Geneva: World Health Organization; 2007.Google Scholar
  53. Dolan KA, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–8.View ArticlePubMedGoogle Scholar
  54. Bundesärztekammer, Richtlinien der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opiatabhängiger. 2010.Google Scholar
  55. Intert, F., personal communication 2014.Google Scholar
  56. Peiffer, U., personal communication 2014.Google Scholar
  57. World Health Organization (WHO), Good governance for prison health in the 21st century. A policy brief on the organization of prison health. Geneva: World Health Organization; 2013.Google Scholar
  58. Fricke, U., et al., Anatomisch-therapeutisch-chemische Klassifikation mit \Tagesdosen für den deutschen Arzneimittelmarkt. 2013, GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO): Berlin. p. 288.Google Scholar
  59. Fachinformation Pegasys® - Roche Pharma AG. 2016.Google Scholar
  60. Fachinformation PegIntron® Clearclick® Fertigpen - MSD SHARP & DOHME GMBH. 2015.Google Scholar
  61. Faggiano F, et al. Methadone maintenance at different dosages for opioid dependence (review). Cochrane Database Syst Rev. 2003;3:CD002208.Google Scholar
  62. Sees KL, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of Opioid dependence. Randomized Controlled Trial JAMA. 2000;283(10):1303–10.PubMedGoogle Scholar
  63. Strain EC, et al. Moderate- vs high-DoseMethadone in the treatment of Opioid dependence a randomized trial. JAMA. 1999;281(11):1000–5.View ArticlePubMedGoogle Scholar
  64. Verster, A. and E. Buning, Richtlinien zur Methadonsubstitution. Euro-Methwork 2000.Google Scholar

Copyright

© The Author(s). 2017

Advertisement